LL-K8-22

• CAT Number: I041373
• Molecular Formula: C37H43N5O
• Molecular Weight: 573.77
• Purity: ≥95%
• Synonyms: 1-[4-[3-(1-adamantyl)propyl]piperazin-1-yl]-2-[4-(4-isoquinolin-4-ylphenyl)pyrazol-1-yl]ethanone
• InChI: InChI=1S/C37H43N5O/c43-36(41-14-12-40(13-15-41)11-3-10-37-19-27-16-28(20-37)18-29(17-27)21-37)26-42-25-33(23-39-42)30-6-8-31(9-7-30)35-24-38-22-32-4-1-2-5-34(32)35/h1-2,4-9,22-25,27-29H,3,10-21,26H2
• InChIKey: WXQLBECTYSLDGB-UHFFFAOYSA-N
• SMILES: C1CN(CCN1CCCC23CC4CC(C2)CC(C4)C3)C(=O)CN5C=C(C=N5)C6=CC=C(C=C6)C7=CN=CC8=CC=CC=C87

LL-K8-22（Cat No.:I041373）is a small molecule inhibitor that targets specific signaling pathways involved in cancer cell proliferation and survival. It is designed to inhibit certain kinases or enzymes that contribute to tumor growth, making it a potential therapeutic candidate for treating various cancers. LL-K8-22 has shown promise in preclinical studies for its ability to selectively block the activity of these critical proteins, thereby reducing tumor progression. Ongoing research is focused on evaluating its efficacy and safety in clinical trials, with the aim of developing it as a targeted cancer therapy.